AstraZeneca Receives “Hold” Rating from Berenberg Bank (AZN)
AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by stock analysts at Berenberg Bank in a report issued on Thursday, AR Network reports. They currently have a GBX 3,570 ($58.57) price objective on the stock. Berenberg Bank’s price objective points to a potential downside of 10.59% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Pareto Securities reiterated a “sell” rating on shares of AstraZeneca in a research note on Monday. They now have a GBX 3,481.07 ($57.11) price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of AstraZeneca in a research note on Friday, February 7th. They now have a GBX 4,150 ($68.09) price target on the stock. Finally, analysts at Societe Generale raised their price target on shares of AstraZeneca from GBX 3,030 ($49.71) to GBX 3,126 ($51.29) in a research note on Friday, February 7th. They now have a “sell” rating on the stock. Eleven equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and six have given a buy rating to the company’s stock. AstraZeneca presently has a consensus rating of “Hold” and a consensus price target of GBX 3,441.08 ($56.46).
Shares of AstraZeneca (LON:AZN) opened at 3993.9998 on Thursday. AstraZeneca has a 52 week low of GBX 2895.00 and a 52 week high of GBX 3964.50. The stock’s 50-day moving average is GBX 3756.62 and its 200-day moving average is GBX 3404.. The company’s market cap is £50.125 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.